Profilo
Ingmar Bruns worked as the Chief Medical Officer at Trillium Therapeutics ULC from 2020 to 2021.
Prior to that, he held the position of Senior Vice President-Clinical Development at Pieris Pharmaceuticals, Inc. Dr. Bruns earned a doctorate degree from Universität zu Lübeck.
Precedenti posizioni note di Ingmar Bruns
| Società | Posizione | Fine |
|---|---|---|
| TRILLIUM THERAPEUTICS | Direttore Tecnico/Scientifico/R&S | 17/11/2021 |
| PIERIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formazione di Ingmar Bruns
| Universität zu Lübeck | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
- Borsa valori
- Insiders
- Ingmar Bruns
